The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

Novo Nordisk agreed to pay up to $2 billion for the rights to ... hormones and is in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in ...

and now it looks like we'll have the next generation of these breakthrough weight loss and diabetes medicines on shelves by early next year. Less than five years on from when Novo Nordisk's ...

The dive in Novo Nordisk's stock price in March 2025 was primarily due to a pipeline setback. Earlier this month, the company reported achieving a 15.7% weight loss in obese and type 2 diabetes ...

In 2024, Novo Nordisk's Ozempic generated nearly $17 billion in sales and Wegovy brought in around $8 billion. Eli Lilly's Type 2 diabetes drug is Mounjaro and the weight-loss version is Zepbound.